Sponsor

Astellas Pharma US, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Astellas Pharma US, Inc. appears in 25 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials25
Recruiting shown3
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

25 shown
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation TherapyNCT06957691 · collaborator · 2026-01-14
RECRUITING
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyNCT06917313 · collaborator · 2025-12-05
RECRUITING
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerNCT06099769 · collaborator · 2023-10-18
RECRUITING
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEFNCT02589977 · collaborator · 2015-11-01
COMPLETED
A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant RecipientsNCT02444143 · collaborator · 2015-05-01
COMPLETED
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate CancerNCT02064582 · collaborator · 2014-05-01
COMPLETED
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)NCT02092181 · collaborator · 2014-03-01
COMPLETED
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide TherapyNCT02099864 · collaborator · 2014-02-05
COMPLETED
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate CancerNCT01949337 · collaborator · 2014-01-22
UNKNOWN
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung CancerNCT01967095 · collaborator · 2013-10-15
COMPLETED
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the ProstateNCT01777217 · collaborator · 2013-02-01
TERMINATED
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)NCT01215721 · collaborator · 2010-10-01
COMPLETED
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 DiabetesNCT01021865 · collaborator · 2010-02-01
COMPLETED
Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese VolunteersNCT01090141 · collaborator · 2009-11-01
COMPLETED
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)NCT00763035 · collaborator · 2009-01-01
TERMINATED
Spaced Education to Optimize Prostate Cancer ScreeningNCT01168323 · collaborator · 2007-01-01
COMPLETED
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent AsthmaNCT00116103 · collaborator · 2005-06-01
COMPLETED
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's DiseaseNCT00087724 · collaborator · 2004-07-01
TERMINATED
Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid ArthritisNCT00036153 · collaborator · 2002-03-01
COMPLETED
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a SulfonylureaNCT00036192 · collaborator · 2002-02-01
COMPLETED
Detection of Ischemia in Asymptomatic DiabeticsNCT00769275 · collaborator · 2000-08-01
COMPLETED
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic HyponatremiaNCT00380575 · collaborator · 2000-08-01
COMPLETED
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone TherapyNCT00048659 · collaborator
TERMINATED
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate CancerNCT00050297 · collaborator
TERMINATED
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With ChemotherapyNCT00257478 · collaborator
COMPLETED

Drugs studied in this sponsor's trials

15 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Astellas Pharma US, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
enzalutamide4
placebo4
regadenoson2
abiraterone1
dobutamine1
erlotinib1
fezolinetant1
leuprolide acetate1
enzalutamide RxCUI 1307298 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 4 trials placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting 4 trials regadenoson RxCUI 640062 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials abiraterone RxCUI 1100072 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial dobutamine RxCUI 3616 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fezolinetant RxCUI 2637134 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial leuprolide acetate RxCUI 203217 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial methotrexate RxCUI 6851 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial micafungin RxCUI 325887 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial mifepristone RxCUI 6964 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial mirabegron RxCUI 1300786 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial prednisone RxCUI 8640 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial solifenacin succinate RxCUI 476588 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial Vesicare RxCUI 539812 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator25
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.